Vanda Puts Dog Studies In Spotlight In Suit Challenging FDA Clinical Hold

Vanda seeks court order requiring US FDA to lift partial clinical hold on its gastroparesis treatment tradipitant; calls on drug makers to oppose agency's animal research policy, saying it requires unjustified killing of dogs.

Beagle puppy lying on the white background among other sleeping puppies - Image

Vanda Pharmaceuticals Inc. filed suit against the US FDA to get the agency to revoke the partial clinical hold it imposed on its gastoparesis drug candidate tradipitant. But it is also using the complaint to campaign against FDA's animal research policy, saying it results in the unnecessary killing of dogs and other animals.

The company issued an open letter to FDA the day it filed the Feb. 5 complaint, in which...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet